Positioning political buying, disclosed 2026-09-04
Options put/call open interest 0.18, read 2026-10-24
Ethical passes the values gate
Price248.52 USD
Fair value237.22
Ethical score92.0/100
RatingQUALITY, FULLY VALUED
Our investment reviews on this name
2026-10-19Read Accumulation248.52+0.0% to today ✓Markup gives way to Accumulation
2026-10-02Read Markup250.74-0.9% to today Distribution gives way to Markup after a 5% rise in 11 days
2026-09-21Read Distribution237.76+4.5% to today Markup gives way to Distribution first Distribution read since July
2026-08-21Read Markup239.08+3.9% to today ✓Distribution gives way to Markup after a 6% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ametek holds its Distribution at $248.52. The statistical read favours the buyers, held for 15 days.
As held on the ledger · 2026-10-15
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 15 days
Price at the screen
$248.52
Valuation
36.33 trailing · 26.03 forward price to earnings
Values screen
PASS· score 92.0
Beta
0.96
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
14.59%
Below 33%
Interest-bearing debt is just 14.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.82%
Below 49%
Money owed to the company is 9.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Ametek clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 15%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-24. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AME's ethical verdict changes
Today AME passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads QUALITY, FULLY VALUED: it trades above our $237.22 fair value estimate, moderate competitive moat, 15.00% revenue growth.
Fair value range in USD, drawn from the 2026-10-15 screen. The gold marker is the market price at the same screen. The price runs 4.5% above the base estimate.
Third-party analyst targets: 18 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Precision Parts Maker Priced for Perfection
Every jet engine and power plant runs on sensors and motors that must work first time, every time. Ametek supplies those critical pieces across aerospace and industrial markets, with solid 11% revenue growth, 20% profit margins and a moderate moat. Yet the shares sit 7% above our fair value at a 26.9 times forward earnings multiple that leaves little room for error.
We pass because the valuation already bakes in continued execution and ignores the moderate competitive edge. Analyst targets sit higher, but history shows specialty industrial names rarely sustain premium multiples when growth settles back toward mid-single digits.
The main risk is cyclical exposure in aerospace and power markets, where any slowdown would quickly expose the stretched multiple. Ethical screen clears, yet price leaves no margin of safety. Analysis, not advice.
AME trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-10-12Markup$248.58-0.9%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-10-02Markup · changed$250.74+5.5%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-08-21Markup · changed$239.08+0.9%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-07-21Distribution$237.00+4.6%Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-07-18Distribution$226.55+0.0%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-07-17Distribution$226.55+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (92). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $259.
2026-07-03Distribution$226.55+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (92). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$226.55Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (92). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
